Multi-Parameter Biochemical Analysis as Diagnostic, Staging, and Prognostic Biomarkers for Breast Cancer
Keywords:
Tumor Necrosis Factor-alpha TNF-alpha, Erythrocyte Sedimentation Rate ESR, Hepcidin, Carcinoembryonic Antigen CEAAbstract
Background: The early diagnosis of breast cancer and the accurate identification of its stage have both been shown to be significant predictors of a patient's survival from breast cancer and also can assist in determining the most effective course of treatment for a patient. Both chronic systemic inflammation and altered iron metabolism can create an environment that supports the development of metastasis in a tumor microenvironment. In addition to reviewing these factors, our research group evaluated a new group of potential biomarkers that included Tumor Necrosis Factor-alpha (TNF-alpha), Erythrocyte Sedimentation Rate (ESR), Hepcidin and Carcinoembryonic Antigen (CEA). We assessed each biomarker's ability to diagnose, stage, and provide prognostic information for healthy control subjects and patients with Breast Cancer who were categorized based on AJCC stages I-IV.
Methods: A single-site prospective case-control study included 240 women who were either healthy age-matched control subjects (60) or had a history of histologically confirmed breast cancer (180, Stage I-IV; 45 per stage). Serum levels of Tumor Necrosis Factor-alpha (TNF-alpha), Hepcidin and Carcinoembryonic Antigen (CEA) were measured using highly sensitive ELISA and MEIA methods. Erythrocyte Sedimentation Rate (ESR) was determined using an automated Westergren method. Statistical analyses included independent t-tests, one-way ANOVA with Tukey's post-hoc comparisons, Pearson correlation analyses and Receiver Operating Curve analysis (including calculation of area under the curve, sensitivity and specificity).
Serum levels of TNF-alpha, ESR, hepcidin and CEA were significantly higher in breast cancer patients than in healthy control subjects (p < 0.001). Also, serum levels increased progressively across the stages of breast cancer pathology (Stage I through IV, p-trend < 0.001). When combined, these four markers provided a greater diagnostic accuracy (AUC = 0.958, sensitivity = 93.3%, specificity = 93.3%) than each marker individually; as indicated by the area under the receiver operating characteristic (ROC) curve analysis. In addition, Hepcidin (AUC = 0.912) and TNF-alpha (AUC = 0.895) demonstrated a significantly improved diagnostic sensitivity in early-stage breast cancer (Stage I-II) when compared to CEA (AUC = 0.784). Finally, there was a strong positive linear correlation between TNF-alpha and Hepcidin (r = 0.741, p < 0.001); thereby demonstrating the relationship between pro-inflammatory signals and tumor-induced iron sequestration.
The use of a combination of traditional oncofetal (CEA) markers, as well as those that reflect the level of inflammation (TNF-alpha, ESR) and the regulation of iron metabolism (hepcidin), provides a highly sensitive and specific multiparametric marker that can be used to assess the dynamics of disease progression. This combined marker has been shown to improve the early diagnosis of breast cancer, to help determine its stage, and to reflect the underlying pathological changes in the breast tissue.